JNJ-5207852 dihydrochloride NEW
| Price | $43 | $76 | $153 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-09 |
Product Details
| Product Name: JNJ-5207852 dihydrochloride | CAS No.: 1782228-76-5 |
| Purity: 99.95% | Supply Ability: 10g |
| Release date: 2025/11/09 |
Product Introduction
Bioactivity
| Name | JNJ-5207852 dihydrochloride |
| Description | JNJ-5207852 dihydrochloride is a novel, non-imidazole histamine H3 receptor antagonist, with high affinity at the rat (pKi=8.9) and human (pKi=9.24) H3 receptor. |
| In vivo | JNJ-5207852 is a potent dibasic amine antagonist that binds potently to rat H3 receptors (Ki=1.2?nm), and has good brain penetration. In ex vivo binding studies in mice, the compound had an ED50 of 0.13?mg?kg?1, subcutaneously. It promotes wakefulness in rodents at 10?mg?kg?1 s.c. but not at 1?mg?kg?1, and significantly, this effect was absent in H3 receptor KO mice. JNJ-10181457 is also a dibasic amine antagonist that exhibits high-affinity binding for the rat H3 receptor (Ki=7.1?nm), promoting wakefulness in rodents and reducing cataplectic attacks in narcoleptic dogs . JNJ-10181457 improved cognitive performance in SHR pups at 10?mg?kg?1[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : Slightly soluble |
| Keywords | toxicity | sleep | REM | low | JNJ-5207852 Dihydrochloride | JNJ5207852 dihydrochloride | JNJ5207852 Dihydrochloride | JNJ-5207852 | JNJ5207852 | JNJ 5207852 Dihydrochloride | JNJ 5207852 dihydrochloride | JNJ 5207852 | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H3 receptor |
| Inhibitors Related | Chlorphenesin | Histamine dihydrochloride | Meclizine dihydrochloride | Mirtazapine | Lidocaine | Famotidine | Mebhydrolin napadisylate | Sodium butanoate | Amitriptyline hydrochloride | Alginic acid | Trazodone hydrochloride | Mianserin hydrochloride |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Parkinson's Disease Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00/25mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $0.00/1gram |
VIP1Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2025-04-14 | |
| $86.00/2mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY